Gacyclidine[3] (GK-11, OTO-313)[4][5] is a psychoactive drug which acts as a dissociative via functioning as a non-competitive NMDA receptor antagonist.

The reduction of (V) with lithium aluminium hydride (LiAlH4) or Raney nickel in isopropanol affords the corresponding amine (VI), preferentially with the cis-configuration.

Gacyclidine is used to reduce damage to the brain or spinal cord, hence a treatment for tinnitus, stroke, trauma, and convulsion.

A lipid-based intratympanic formulation of gacyclidine (OTO-313) has been studied as a potential therapy for the treatment of tinnitus.

In addition, no neuronal or glial alterations, such as astrocytic swelling or microglial activation, were seen that could suggest a short-term toxic event had occurred.

Outside of results seen in animals like potential trauma assistance and pain relief, there is little to no proof that there will be any clinical benefits in the future of Gacyclidine.

The results of Gacyclidine are helpful in reducing the size of the lesion and enhancing the functional parameters after injury.

Gacyclidine also increases behavioral parameters and neuronal survival in traumatic brain injury models.